Tsung Tan’s Post

ᴡʜᴀᴛ ɪꜱ ᴄᴇʟᴇᴄᴏxɪʙ? Celecoxib is a nonsteroidal anti-inflammatory drug (NSAID) that specifically inhibits the cyclooxygenase-2 (COX-2) enzyme. It is primarily used to relieve pain, reduce inflammation, and improve function in conditions such as arthritis, acute pain, and menstrual discomfort. Unlike traditional NSAIDs, which inhibit both COX-1 and COX-2, celecoxib has a more targeted action, which may reduce the risk of gastrointestinal side effects associated with non-selective NSAIDs. It is important to use celecoxib under medical supervision due to potential cardiovascular and gastrointestinal risks.

FDA Approves, the 1st and only, ready to use, Vabysmo PFS for 3 Leading Causes of Vision Loss Jul 8, 2024 They include Wet, or neovascular, age-related macular degeneration (AMD), diabetic macular edema (DME), and macular edema following retinal vein occlusion (RVO). Vabysmo (faricimab-svoa - Genetech) is the first bispecific antibody.  It targets and inhibits two signaling pathways linked to a number of vision-threatening retinal conditions by neutralizing angiopoietin-2 (Ang-2) and vascular endothelial growth factor-A (VEGF-A). Ang-2 and VEGF-A are thought to contribute to vision loss by destabilizing blood vessels. It may cause new leaky blood vessels to form and increase inflammation. By blocking pathways involving Ang-2 and VEGF-A, Vabysmo is designed to stabilize blood vessels. #visionloss #agerelatedmaculardegeneration #diabeticmacularedema #researchanddevelopment #innovation #pfs #healthcare #lifesciences #innovation #fdaapproval #monoclonalantibody #qualityoflife

Daily Dose 💉 of Internal Medicine: Drug-induced lupus erythematosus (DILE) DILE is a rare condition caused by certain medications. Here are some medications associated with DILE: 1. Hydralazine 2. Procainamide 3. Isoniazid 4. Minocycline 5. Quinidine 6. Chlorpromazine 7. Methyldopa 8. D-penicillamine 9. Tumor necrosis factor (TNF) inhibitors 10. Anti-TNF-alpha agents like infliximab, etanercept, adalimumab. It's important to note that not everyone who takes these medications will develop DILE, and the condition typically resolves after discontinuation of the offending drug. #medicine #healthcare

🚨 New FDA Approval: Duvyzat (givinostat) for Duchenne Muscular Dystrophy (DMD) #FDA #DRxVlogs Pragya Pandey Duvyzat is now approved for DMD patients aged 6 and older. Here's what this means: Non-steroidal Option: Duvyzat is the first non-steroidal drug approved for DMD, offering an alternative for patients who can't tolerate or don't respond to steroids. Targets Disease Progression: It works as a histone deacetylase (HDAC) inhibitor, reducing inflammation and muscle loss – key issues in DMD. Clinical Results: Studies showed Duvyzat slowed functional decline in DMD patients compared to placebo. Important Note: Duvyzat is not a cure. Potential side effects include diarrhea and low blood cell counts.

Zetomipzomib is the only selective immunoproteasome inhibitor being evaluated in clinical trials for lupus nephritis. Learn more about the PALIZADE trial at https://lnkd.in/gtxDfybE. #PALIZADEtrial #zetomipzomib #LupusNephritis

In collaborative work with experts in Brazil and Spain, our team showed that Ericaria selaginoides (ES) aqueous extracts and derived biogenic gold nanoparticles (Au@ES) reduce inflammation and oxidative stress in a murine model of inflammatory bowel disease (BD). Interestingly, their positive impact is visible also on the myenteric plexus. These findings suggest ES and Au@ES as potential alternative therapies for IBD. https://lnkd.in/dzn9hUe5

A hot new entry in the Weight loss medications class! MariTide is a dual agent - both a glucagon-like peptide 1 (GLP-1) receptor agonist and glucose-dependent insulinotropic polypeptide receptor (GIPR) antagonist. 20% body weight reduction at 1 year, and still going down. In DM patients, 17% weight reduction and 2.2% HbA1c reduction.

Potential new entry which will decrease the cost of challengers in this field. Keep in mind that lifestyle changes are always useful and mandatory

#ACR24 Abstracts Now Available: Efficacy, safety, and pharmacokinetics of anti-CD40 antibody in patients with Rheumatoid Arthritis: A phase 2, randomized, placebo-controlled 12-week-treatment proof-of-concept study. View here: https://bit.ly/3YLmvNM

Hypoparathyroidism is a condition in which the parathyroid glands fail to produce sufficient levels of #PTH (#parathyroid hormone). This, along with vitamin D and calcitonin, work to regulate bone growth and bone cell activity. Calcium and vitamin D supplements are the current standard of care, though their uses are associated with long-term comorbidities such as cardiovascular, renal, neurologic and skeletal issues. To date, only one PTH injectable is market approved; Takeda’s Natpara. There are two other candidates, Ascendis’ TransCon, which has submitted an NDA (PDUFA in May 2024) and Amolyt’s Eneboparatide which is initiating Phase 3 clinical trials (topline data in 2025). Entera’s EB612 is being developed as the first oral PTH(1-34) peptide replacement treatment for #hypoparathyroidism. Entera expects to submit data from the Phase 1 of its next generation EB612 program using the naked #PTH(1-34) peptide in the first half of 2024.